Academic Journal
Measurable Residual Disease Testing in Multiple Myeloma Routine Clinical Practice: A Modified Delphi Study
| Title: | Measurable Residual Disease Testing in Multiple Myeloma Routine Clinical Practice: A Modified Delphi Study |
|---|---|
| Authors: | Karthik Ramasamy, Hervé Avet-Loiseau, Cecilie Hveding Blimark, Michel Delforge, Francesca Gay, Salomon Manier, Joaquín Martinez-Lopez, Maria Victoria Mateos, Mohamad Mohty, Niels W.C.J. van de Donk, Katja Weisel |
| Source: | HemaSphere, Vol 7, Iss 9, p e942 (2023) |
| Publisher Information: | Wiley, 2023. |
| Publication Year: | 2023 |
| Collection: | LCC:Diseases of the blood and blood-forming organs |
| Subject Terms: | Diseases of the blood and blood-forming organs, RC633-647.5 |
| More Details: | We used a modified Delphi approach to establish areas of consensus and nonconsensus regarding the utility of determining measurable residual disease (MRD) to assess multiple myeloma (MM) treatment response, which may inform disease management and design of future clinical trials. This modified Delphi study incorporated 2 iterative rounds of surveys to evaluate the opinions of an expert panel of 61 practicing hematological oncologists from across 14 countries in Europe concerning the use of MRD testing in MM management. Survey 1 assessed experts’ opinions on MRD testing in different clinical situations and associated challenges. Survey 2 focused on the lack of consensus areas identified in survey 1. Consensus to an individual question was defined a priori as 75% agreement or disagreement by the panel. From the 2 rounds of surveys, the experts reached consensus agreement that MRD testing should be performed in newly diagnosed or relapsed patients who achieved complete response (CR) or better after transplantation. In transplant-ineligible patients, experts recommended MRD testing in those who are ≤70 years old and in CR. If a patient was previously positive on positron-emission tomography and computed tomography (PET/CT), both MRD and PET/CT should be assessed at CR. MRD testing should be performed ≤6 months after transplantation and every 6–12 months in continuously treated patients in CR. There was no consensus on making treatment decisions based on MRD status. MRD testing is an important component of clinical management in MM. Additional data will further clarify the role of MRD in guiding treatment decisions. |
| Document Type: | article |
| File Description: | electronic resource |
| Language: | English |
| ISSN: | 2572-9241 00000000 |
| Relation: | http://journals.lww.com/10.1097/HS9.0000000000000942; https://doaj.org/toc/2572-9241 |
| DOI: | 10.1097/HS9.0000000000000942 |
| Access URL: | https://doaj.org/article/f62092dd32894195b5a254c9595e4e6c |
| Accession Number: | edsdoj.f62092dd32894195b5a254c9595e4e6c |
| Database: | Directory of Open Access Journals |
| ISSN: | 25729241 00000000 |
|---|---|
| DOI: | 10.1097/HS9.0000000000000942 |
| Published in: | HemaSphere |
| Language: | English |